Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience.

Saved in:
Bibliographic Details
Title: Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience.
Authors: Yuen CA; Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons., Hsu JM; Department of Hematology Oncology., Van Besien K; Department of Hematology Oncology., Reshef R; Department of Hematology Oncology, Columbia University Vagelos College of Physicians and Surgeons., Iwamoto FM; Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons., Haggiagi A; Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons., Liechty B; Departments of Pathology., Zhang C; Neurology, Weill Cornell Medicine., Wesley SF; Division of Neuroimmunology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York-Presbyterian Hospital, New York, NY., Magge R; Department of Neurology, Weill Cornell Brain Tumor Center.
Source: Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 2022 Jun 01; Vol. 45 (5), pp. 254-262. Date of Electronic Publication: 2022 Apr 11.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9706083 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-4513 (Electronic) Linking ISSN: 15249557 NLM ISO Abbreviation: J Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1537-4513
DOI:10.1097/CJI.0000000000000416